7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pérdida de audición tras gentamicina intratimpánica en la Enfermedad de Ménière. Estudio retrospectivo Translated title: Hearing loss after intratympanic gentamicin in Ménière's disease. Retrospective study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN: Introducción y objetivo: La enfermedad de Ménière (EM) se caracteriza por crisis de vértigo recurrentes acompañadas de acúfenos, pérdida de audición y sensación de plenitud ótica. Dentro de las opciones terapéuticas se hablará, entre otras, de inyección de gentamicina intratimpánica (ITG). El objetivo es evaluar la pérdida de audición tras la ITG en pacientes con EM. Método: Se estudiaron 33 pacientes con EM definitiva a los cuales se les administró ITG. Se valoró la pérdida de audición al mes de la ITG, a los 6, 12 y 24 meses. Resultados: De los 33 pacientes analizados, el 78,8% presentaban EM unilateral; el 21,2%, bilateral. El 48,5% fueron mujeres; el 51,5%, hombres. El 39,4% ya habían sido tratados con betahistina y corticoides. 9 pacientes presentaron crisis de Tumarkin antes de la ITG. Se comparó el PTA (Pure Tone Average) previo a la administración de ITG con el obtenido a los 2 años y la audición disminuyó de 57,50 dB a 62,58 dB. 9 pacientes precisaron una segunda tanda de ITG, con una pérdida de audición desde 66,72 dB a 68,96 dB. Y tras esto, 3 pacientes necesitaron una tercera tanda, pasando la audición de 63,75dB a 72,50 dB. Conclusiones: La utilización de ITG en la EM y provoca una caída del PTA de alrededor de 5 dB a expensas de una mejoría en la frecuencia e intensidad de las crisis de vértigo.

          Translated abstract

          SUMMARY: Introduction and objective: Ménière's disease (MS) is characterized by recurrent vertigo attacks with tinnitus, hearing loss and aural fullness. Among the therapeutic options, intratympanic injection of gentamicin (ITG) will be discussed, among others. The objective is to evaluate hearing loss after ITG in patients with MS. Method: 33 patients of the Otorhinolaryngology and Head and Neck Surgery Service of the Hospital Clínico Universitario de Salamanca will be studied, all of them with definitive MS to whom ITG was administered. Hearing loss will be assessed one month after the ITG, at 6, 12 and 24 months. Results: Of the 33 patients analyzed, 78.8% had unilateral MS; 21.2%, bilateral. 48.5% were women; 51.5%, men. 39.4% had already been treated with betahistine and corticosteroids. 9 patients presented Tumarkin crisis before ITG. The PTA (Pure Tone Average) prior to ITG administration was compared with that obtained at 2 years and hearing decreased from 57.50 dB to 62.58 dB. 9 patients required a second round of ITG, with a hearing loss ranging from 66.72 dB to 68.96 dB. And after this, 3 patients needed a third wave, hearing from 63.75dB to 72.50 dB. Conclusions: The use of ITG in MS causes a fall in PTA of around 5 dB at the expense of an improvement in the frequency and intensity of vertigo attacks.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Article: not found

          International consensus (ICON) on treatment of Ménière's disease

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Betahistine for symptoms of vertigo.

            Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Pathophysiology of M??ni??re's Syndrome: Are Symptoms Caused by Endolymphatic Hydrops?

                Bookmark

                Author and article information

                Journal
                orl
                Revista ORL
                Rev. ORL
                Ediciones Universidad de Salamanca (Salamanca, Salamanca, Spain )
                2444-7986
                September 2021
                : 12
                : 3
                : 243-252
                Affiliations
                [1] Salamanca orgnameComplejo Asistencial Universitario de Salamanca España
                Article
                S2444-79862021000300004 S2444-7986(21)01200300004
                10.14201/orl.26043
                8914b8be-8bc3-4839-b0e9-dd52144d5d32

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

                History
                : 16 March 2021
                : 01 May 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 25, Pages: 10
                Product

                SciELO Spain

                Categories
                Artículo original

                audiometría,Meniere Disease,gentamicin,audiometry,Enfermedad de Ménière,gentamicina

                Comments

                Comment on this article